NCT02917421 2026-04-17
ART
Weill Medical College of Cornell University
Phase 1/2 Active not recruiting
Clinical Trials
10 trialsNCT06492759 2026-04-17
High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer
Emory University
Phase 2 Recruiting
NCT04852887 2026-04-15
DEBRA
NRG Oncology
Phase 3 Recruiting
NCT03488693 2026-04-14
TAILOR RT
Canadian Cancer Trials Group
Phase 3 Recruiting
NCT00310180 2026-04-13
TAILORx
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT02954874 2026-04-13
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT03598257 2026-04-13
Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04052555 2026-04-13
Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT05406232 2026-04-09
Temporal Immunologic Changes With Hypofractionated Radiation-Induced DNA Damage in Breast Cancer
M.D. Anderson Cancer Center
Recruiting
NCT04266249 2026-03-23
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting